412 related articles for article (PubMed ID: 31570105)
21. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.
Zheng B; Liu XL; Fan R; Bai J; Wen H; Du LT; Jiang GQ; Wang CY; Fan XT; Ye YN; Qian YS; Wang YC; Liu GJ; Deng GH; Shen F; Hu HP; Wang H; Zhang QZ; Ru LL; Zhang J; Gao YH; Xia J; Yan HD; Liang MF; Yu YL; Sun FM; Gao YJ; Sun J; Zhong CX; Wang Y; Kong F; Chen JM; Zheng D; Yang Y; Wang CX; Wu L; Hou JL; Liu JF; Wang HY; Chen L
Clin Cancer Res; 2021 Jul; 27(13):3772-3783. PubMed ID: 33947693
[TBL] [Abstract][Full Text] [Related]
22. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
Front Immunol; 2021; 12():673248. PubMed ID: 34211467
[TBL] [Abstract][Full Text] [Related]
23. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
[TBL] [Abstract][Full Text] [Related]
24. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract][Full Text] [Related]
25. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma.
Trevisan França de Lima L; Broszczak D; Zhang X; Bridle K; Crawford D; Punyadeera C
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188451. PubMed ID: 33065194
[TBL] [Abstract][Full Text] [Related]
26. Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma.
Chae H; Sung PS; Choi H; Kwon A; Kang D; Kim Y; Kim M; Yoon SK
Ann Lab Med; 2021 Mar; 41(2):198-206. PubMed ID: 33063681
[TBL] [Abstract][Full Text] [Related]
27. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
28. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma.
Lee YR; Kim G; Tak WY; Jang SY; Kweon YO; Park JG; Lee HW; Han YS; Chun JM; Park SY; Hur K
Int J Cancer; 2019 Mar; 144(6):1444-1452. PubMed ID: 30338850
[TBL] [Abstract][Full Text] [Related]
29. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
Dhayat SA; Yang Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
[TBL] [Abstract][Full Text] [Related]
30. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
31. MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma.
Kim SS; Eun JW; Choi JH; Woo HG; Cho HJ; Ahn HR; Suh CW; Baek GO; Cho SW; Cheong JY
Sci Rep; 2020 Oct; 10(1):17862. PubMed ID: 33082400
[TBL] [Abstract][Full Text] [Related]
32. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
33. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
Li J; Han X; Yu X; Xu Z; Yang G; Liu B; Xiu P
J Exp Clin Cancer Res; 2018 Sep; 37(1):213. PubMed ID: 30176913
[TBL] [Abstract][Full Text] [Related]
34. Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
Jeepalyam S; Sheel A; Ejaz A; Miller E; Manne A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762533
[TBL] [Abstract][Full Text] [Related]
35. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
[TBL] [Abstract][Full Text] [Related]
36. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
Wang Y; Zhou K; Wang X; Liu Y; Guo D; Bian Z; Su L; Liu K; Gu X; Guo X; Wang L; Zhang H; Tao K; Xing J
Cancer Sci; 2021 Nov; 112(11):4772-4784. PubMed ID: 34490703
[TBL] [Abstract][Full Text] [Related]
37. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
38. eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA.
Mizuno K; Akamatsu S; Sumiyoshi T; Wong JH; Fujita M; Maejima K; Nakano K; Ono A; Aikata H; Ueno M; Hayami S; Yamaue H; Chayama K; Inoue T; Ogawa O; Nakagawa H; Fujimoto A
Sci Rep; 2019 Oct; 9(1):15017. PubMed ID: 31641155
[TBL] [Abstract][Full Text] [Related]
39. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
[TBL] [Abstract][Full Text] [Related]
40. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
